New hope for myeloma patients out of options: experimental drug enters human testing
NCT ID NCT07336472
Summary
This is a first-in-human study to test a new drug called IBI3003 for adults with multiple myeloma that has returned or stopped responding to at least three prior treatments. The first part aims to find a safe and tolerable dose. The second part will explore if the drug can help control the cancer. The study will enroll up to 360 participants at multiple centers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.